Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

The oncology biomarkers market is experiencing rapid expansion, driven by advancements in cancer detection and personalized treatment. As cancer continues to be a major global health challenge, innovations in biomarkers are becoming crucial for early diagnosis and effective therapeutic strategies. Below, we explore the market size, key drivers, industry trends, major players, and regional insights shaping this important sector.

Oncology Biomarkers Market Size and Growth Projections

The oncology biomarkers market has seen significant growth in recent years and is expected to continue on this trajectory. From a valuation of $17.3 billion in 2025, it is projected to rise to $19.73 billion in 2026, representing a compound annual growth rate (CAGR) of 14.1%. Looking further ahead, the market is anticipated to reach $33.63 billion by 2030, with a slightly higher CAGR of 14.3%. This surge reflects the expanding scope of cancer screening initiatives, progress in molecular biology research, greater access to biomarker testing technologies, and stronger collaborations between research institutions and healthcare providers.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12493&type=smp

Key Factors Fueling Growth in Oncology Biomarkers

One of the major forces propelling the oncology biomarkers market is the increasing incidence of cancer worldwide. Cancer involves the uncontrolled growth of abnormal cells, which can spread throughout the body. Biomarkers help provide detailed insights into the type and characteristics of different cancers by analyzing genes, proteins, and other substances in patients. For example, a February 2024 report from the World Health Organization, based in Switzerland, projects more than 35 million new cancer cases by 2050—an increase of 77% from the estimated 20 million cases in 2022. This rising cancer burden is a critical driver encouraging the development and adoption of oncology biomarkers.

Additional Growth Drivers Supporting Market Expansion

Beyond the rising prevalence of cancer, several other factors are stimulating the market. Increasing demand for personalized cancer treatment options is pushing the use of precision diagnostics. Meanwhile, the integration of artificial intelligence for biomarker discovery, rising investments in cancer genomics research, and broader use of liquid biopsy technologies are all contributing to market growth. Furthermore, heightened focus on early detection and ongoing cancer monitoring is fueling demand for more sophisticated biomarker tests and applications.

Access The Complete Oncology Biomarkers Market Report:

https://www.thebusinessresearchcompany.com/report/oncology-biomarkers-global-market-report

Segments Defining the Oncology Biomarkers Market

This market is segmented based on biomarker types, cancer types, applications, and end users. By biomarker type, categories include protein biomarkers, genetic biomarkers, and other types such as metabolomic, epigenetic, and microRNA biomarkers. Cancer types cover a wide range, including breast, lung, colorectal, prostate, melanoma, leukemia, ovarian, liver cancers, and others. Applications span diagnostics, research and development, prognostics, risk assessment, and more. End users typically comprise hospitals, academic and cancer research centers, and diagnostic laboratories. Further subsegments under protein biomarkers include tumor-specific antigens, circulating tumor cells, and enzymatic biomarkers, while genetic biomarkers involve DNA mutations, gene expression profiles, and single nucleotide polymorphisms.

Emerging Industry Trends Shaping Oncology Biomarkers Demand

Leading companies in the oncology diagnostics field are focusing heavily on developing advanced biomarker assays to enhance early cancer detection and monitor minimal residual disease (MRD), which refers to cancer cells remaining post-treatment that may cause relapse. In May 2024, Tempus, a US-based company specializing in AI and precision medicine, introduced a portfolio of MRD tests, including the xM and xM (NeXT Personal Dx) assays developed by Personalis. These tests feature both tumor-naïve and tumor-informed approaches designed to detect early recurrence and track patient response to immunotherapy. Utilizing circulating tumor biomarkers, these assays provide clinicians with sensitive and actionable information to guide treatment decisions.

Prominent Players Leading the Oncology Biomarkers Market

The oncology biomarkers market includes several key global companies such as F Hoffmann-La Roche AG, Novartis AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Siemens Healthcare GmbH, Becton Dickinson and Company, GE Healthcare Technologies Inc., Eurofins Scientific SE, Agilent Technologies Inc., Hologic Inc., Illumina Inc., bioMerieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN NV, Exact Sciences Corporation, Sysmex Corporation, PerkinElmer Inc., Leica Biosystems, Myriad Genetics Inc., Guardant Health Inc., Enzo Biochem Inc., Biocartis Group NV, Agendia Inc., Epigenomics AG, and OncoDNA SA. These organizations are actively investing in research and technological innovation to maintain their market presence and drive growth.

Regional Breakdown Highlighting Oncology Biomarkers Market Leaders

In 2025, North America dominated the oncology biomarkers market in terms of revenue and market share. Alongside North America, other key regions featured in market analyses include Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East, and Africa. While North America leads currently, emerging markets in Asia-Pacific are expected to exhibit significant growth potential in the coming years.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model